Search Results for “HIV” – Page 3 – media

Vaccine Against HIV

A research group from St.Petersburg Polytechnic University led by Professor Andrei Kozlov has published their study’s findings regarding HIV vaccine creation.
- Source: News Medical
- 685
- August 2, 2018
HIV Researches vaccines
Merck Presents 96-Week Doravirine HIV Data Three Months before PDUFA Date

96-week data on doravirine, Merck’s HIV drug, was posted by the drugmaker recently. Merck expects it to outrun drugs like Bristol-Myers Squibb’s Sustiva in combination regimens and antiretroviral drugs from AbbVie and Johnson & Johnson in viral suppression.
- Source: FierceBiotech
- 897
- July 27, 2018
HIV Merck Researches
Updated HIV Guidelines Recommend Immediate Treatment, Three-Drug Therapy

The 2018 Recommendations of the International Antiviral Society-USA (IAS-USA) suggests that early treatment in adult HIV patients brings about rapid and more definite decrease in viral load and better care of the patient.
- Source: MDEdge
- 784
- July 27, 2018
HIV Policies
Future HIV Drugs by Targeting the Capsid

Current HIV drugs usually act on enzymes needed by the virus throughout its survival. But no drug targets the outermost layer of the virus named the capsid, which protects the genetic material delivered into the host.
- Source: FiercePharma
- 865
- July 17, 2018
HIV Researches
Anti-HIV Drug Increases Life Expectancy

The research work under the lead investigator Amy Zheng of the Massachusetts General Hospital (MGH) Medical Practice Evaluation Center in Boston indicated that the Dolutegravir-based regimen would increase the life expectancy of HIV victims by 2.8 years and prevent 13,000 new HIV infections over 5 years. It was also revealed that this first-line treatment would be cost-effective in 2 years and cost-saving over 5 years.
- Source: medicalxpress
- 681
- June 8, 2018
HIV New Approvals
HIV Therapy – A Major Breakthrough

In 2015, it was reported that around 36.7 million people throughout the world were affected with AIDS, among which 1.1 million were stated as deceased. The majority of AIDS cases were recorded in various African countries followed by India.
- Source: Ddu
- 664
- May 30, 2018
HIV Researches Sanofi
Safer HIV drugs taken off the shelf by Gilead

It has been stated by the patients that Gilead concealed crucial information that the TDF drugs could trigger kidney and bone risks. A safer alternative in the form of TAF could have been incorporated while marketing Truvada and Atripla. The research into TAF was deliberately stopped and the drugs are not likely to be brought to the shelf in the near future.
- Source: drugdu
- 862
- May 11, 2018
Company Insights Gilead HIV
Mylan Introduces Symfi™ Triple Combo Once-Daily HIV Treatment in the U.S.

Global pharmaceutical company Mylan N.V. (MYL) today announced that it will introduce in the U.S. a third cost-saving HIV combination. The U.S. Food and Drug Administration (FDA) approved Symfi™ (efavirenz, lamivudine and tenofovir disoproxil fumarate) 600 mg/300 mg/300 mg tablets, a once-daily, single-tablet regimen (STR), indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 40 kg.
- Source: finance.yahoo
- 541
- March 29, 2018
HIV-1 New Approvals Symfi™
HIV linked to higher risks for obesity, cardiovascular disease

HIV infection is associated with a greater risk for abdominal obesity and, perhaps indirectly, a greater risk for elevated LDL cholesterol and hypertriglyceridemia, according to recent findings.
- Source: healio
- 534
- March 13, 2018
cardiovascular disease HIV obesity Researches
FDA approves new HIV treatment for patients who have limited treatment options

Today, the U.S. Food and Drug Administration approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV). Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications.
- Source: Prnewswire
- 484
- March 8, 2018
antiretroviral HIV New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.